The UK’s National Institute for Health and Care Excellence (NICE) has approved a groundbreaking twice-daily pill, Truqap, that slows the spread of an incurable type of breast cancer.
Developed by AstraZeneca, the drug targets the AKT protein, which fuels cancer cell growth.
How the Drug Works
– AKT Inhibition: Truqap inhibits the AKT protein, slowing or halting disease progression.
– Combination Therapy: When combined with hormone therapy fulvestrant, Truqap extended the period before cancer advancement by 4.2 months compared to fulvestrant and a placebo.
Eligibility and Benefits
– Genetic Mutations: The drug is suitable for patients with PIK3CA, AKT1, or PTEN gene mutations, found in about half of patients with this form of breast cancer.
– Patient Benefits: Up to 3,000 women annually could benefit from Truqap, which can keep cancer from progressing for longer.
Reaction from Experts
– Claire Rowney, CEO of Breast Cancer Now, welcomed the approval but expressed concern about initial rejection delays and urged prompt genetic testing.
– Nicholas Turner, from the Institute of Cancer Research (ICR) and Royal Marsden NHS Foundation Trust, hailed the approval as a “game-changer” for NHS patients with advanced breast cancer.
– Paul Workman, former ICR CEO and researcher, celebrated the landmark moment, saying the drug could improve lives of many NHS patients.